Non-Hodgkin Lymphoma Therapeutics Market Outlook:
Non-Hodgkin Lymphoma Therapeutics Market size was over USD 11.13 billion in 2025 and is anticipated to cross USD 22.94 billion by 2035, witnessing more than 7.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of non-hodgkin lymphoma therapeutics is assessed at USD 11.88 billion.
The market’s growth is attributed to the increasing prevalence of non-hodgkin lymphoma. During the past few years, the world has witnessed a significant surge in the non-hodgkin lymphoma.
As per our survey, non-hodgkin lymphoma is amongst the most common hematological malignancy across the globe and accounts for about 3% of cancer deaths and diagnoses. Further, according to the American Cancer Society, there will be roughly 80,620 NHL diagnoses in 2024 (44,590 men and 36,030 women). This applies to both kids and adults.
Furthermore, there has been surge in research in this field in order to deal with the growing cases. For instance, Researchers funded by the NCI are improving our knowledge of lymphoma treatment. The lymph system, that's a component of the body's immune system, is the place where all lymphomas begin. Scientists are now able to create more individualized treatments for different subtypes of lymphoma owing to advances in understanding the gene alterations that might cause the disease. All this is leading to non-Hodgkin lymphoma therapeutics market growth.
